The U.S. Food and Drug Administration approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection, for the treatment of relapsing forms of multiple sclerosis, the agency announced Thursday.Tyruko was approved to treat adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Like Tysabri, the biosimilar is also indicated for treating moderately […]
